RVX Share Price

Open 1.69 Change Price %
High 1.75 1 Day -0.02 -1.16
Low 1.69 1 Week -0.01 -0.58
Close 1.71 1 Month -0.09 -5.00
Volume 16975 1 Year -0.01 -0.58
52 Week High 2.47
52 Week Low 1.10
RVX Important Levels
Resistance 2 1.77
Resistance 1 1.74
Pivot 1.72
Support 1 1.68
Support 2 1.65
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
BTO 3.38 1.81%
BTO 3.38 1.81%
SC 60.83 -0.44%
PRE 0.64 0.00%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
DA-A 0.23 35.29%
ANX 0.06 20.00%
ANX 0.06 20.00%
CUM 0.90 13.92%
CUM 0.90 13.92%
CXA-B 1.10 11.11%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
PWC 0.10 -16.67%
PWC 0.10 -16.67%
TOS 2.25 -11.42%
TOS 2.25 -11.42%
BX 0.85 -10.53%
BX 0.85 -10.53%
CET 0.48 -9.43%
CET 0.48 -9.43%
DNT 0.10 -9.09%
More..

Resverlogix Corp (TSE: RVX)

RVX Technical Analysis 2
As on 7th Dec 2016 RVX Share Price closed @ 1.71 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.47 & Strong Sell for SHORT-TERM with Stoploss of 1.92 we also expect STOCK to react on Following IMPORTANT LEVELS.
RVX Target for December
1st Target up-side 1.98
2nd Target up-side 2.16
3rd Target up-side 2.33
1st Target down-side 1.48
2nd Target down-side 1.3
3rd Target down-side 1.13
RVX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.resverlogix.com
RVX Address
RVX
279 Midpark Way S.E.
Suite 202
Calgary, AB T2X 1M2
Canada
Phone: 403-254-9252
Fax: 403-256-8495
Interactive Technical Analysis Chart Resverlogix Corp ( RVX TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Resverlogix Corp
RVX Business Profile
Resverlogix Corp., a clinical stage cardiovascular company, develops compounds, which include a therapeutic increase in Apolipoprotein A-I. It primarily develops RVX-208, a small molecule that has completed a Phase IIb clinical trial SUSTAIN and is undergoing a second Phase IIb trial ASSURE for the treatment of atherosclerosis and other chronic diseases, such as neurodegenerative disorders, diabetes mellitus, and Alzheimer's disease. The company is headquartered in Calgary, Canada.